Debjit Chattopadhyay is a Managing Director and Senior Healthcare Analyst of H.C. Wainwright & Co. Debjit Chattopadhyay is focused on health care research at HCW, specializing in biotechnology with a core focus on gene therapy, immune-oncology and rare diseases. Dr. Chattopadhyay has been a Wall Street health care analyst, on sellside, since 2006. In this exclusive interview with the Wall Street Transcript, Dr. Chattopadhyay details the cutting edge of biotech and his stock recommendations in that field.
Dr. Chattopadhyay’s previous sellside experience includes Janney Montgomery Scott, Roth Capital Partners and Boenning & Scattergood. Most recently, Dr. Chattopadhyay was the Managing Director and head of biotechnology at Janney Montgomery Scott. Dr. Chattopadhyay received his Ph.D. from the University of Connecticut and has served as an oncology research fellow at Memorial Sloan Kettering Cancer Center and also holds a Master of Business Administration — MBA — degree from Drexel University.
“I see basically two different approaches right now. One is in vivo gene therapy, which is all the adeno-associated vector-based gene therapy guys. The other is more ex vivo gene therapy, whereby you are modifying stem cells from patients outside the body with the lentiviral vectors and then sending those modified cells back into the patient, which is being done by bluebird bio (NASDAQ:BLUE) and some others like Rocket (NASDAQ:RCKT).”
The adeno-associated vector-based gene therapy sector is also of interest to Dr. Chattopadhyay.
“Amongst the adeno-associated viruses, it’s just the choice of vectors, promoters and gene that differentiates the players, but the overarching approach is similar. So there are literally two real buckets here, ex vivo and in vivo gene therapy, in the clinic currently.”
“The other incoming third bucket is the gene editing…But, overall, the trends suggest that scientists and clinicians are figuring it out and getting consistent data. That is what matters: data consistency without unexpected safety issues. ”
Read the complete interview with all the current stock picks in the Wall Street Transcript.
Mizuho Securities Managing Director Dr. Difei Yang Picks the Winners in the Gene Therapy Stock Sector
October 02, 2018
H.C. Wainwright Managing Director of Equity Research and Senior Healthcare Analyst Raghuram Selvaraju, Ph.D., MBA Reveals his Top Picks
October 02, 2018
Biotechnology Equity Research Expert, Yun Zhong, Ph.D., Picks Gene Therapy Stocks for Investors
March 22, 2019
Wedbush Managing Director Dr. David Nierengarten Bangs the Table for His Gene Therapy Stock Winners
October 02, 2018
Fabry Disease, Gaucher Disease, Pompe Disease and Cystinosis: AVROBIO has One Gene Therapy Platform to Treat them All
November 01, 2018
